Novavax
NVAX
245 hedge funds and large institutions have $632M invested in Novavax in 2025 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 70 increasing their positions, 67 reducing their positions, and 36 closing their positions.
36% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 36
5% more funds holding
Funds holding: 234 → 245 (+11)
4% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 67
2.81% less ownership
Funds ownership: 64.13% → 61.31% (-2.8%)
15% less call options, than puts
Call options by funds: $45.3M | Put options by funds: $53.3M
23% less capital invested
Capital invested by funds: $826M → $632M (-$194M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Coatue Management
New York
|
+$31.7M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$20.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$6.73M |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$5.14M |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
+$4.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$28.4M |
| 2 |
Morgan Stanley
New York
|
-$24.5M |
| 3 |
D.E. Shaw & Co
New York
|
-$20.9M |
| 4 |
Renaissance Technologies
New York
|
-$7.46M |
| 5 |
Citigroup
New York
|
-$5.74M |
NVAX Hedge Fund Activity: Q1 2025 in Review
245 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q1 2025, worth a combined $632M — down 23% from $826M a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new NVAX positions and 36 closed out — a net gain of 13 holders — while 70 added to existing stakes and 67 trimmed.
The largest buyer was Coatue Management, opening a new position worth an estimated $31.7M. The largest seller was UBS Group, cutting an estimated $28.4M.
- 245 institutional investors held Novavax (NVAX) as of Q1 2025, up from 234 in Q4 2024.
- Funds reported $632M of Novavax stock for Q1 2025, down 23% quarter-over-quarter.
- 49 funds opened new Novavax positions in Q1 2025 and 36 closed out, a net change of +13 holders.
- The largest Novavax buyer in Q1 2025 was Coatue Management, an estimated $31.7M added.
- The largest Novavax seller in Q1 2025 was UBS Group, an estimated $28.4M sold.
Based on aggregated 13F filings for Q1 2025.